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Abstract
Background: Epidemiological studies have shown an inverse relationship between vitamin D levels and
cardiovascular diseases. However, this does not infer a causal relationship between the two. Chronic kidney disease
(CKD) patients have a high prevalence of vitamin D deficiency and carotid atherosclerosis. Therefore, in this study
we have aimed to determine the association between serum 25-hydroxyvitamin D levels and carotid atherosclerosis
in the CKD population.
Methods: 100 CKD stage 3–4 patients were included in the study. Direct chemiluminesent immunoassay was used to
determine the level of serum 25-hydroxyvitamin D. All subjects underwent a carotid ultrasound to measure common
carotid artery intima-media thickness (CCA-IMT) and to assess the presence of carotid plaques or significant stenosis
(≥50 %). Vitamin D deficiency was defined as serum 25-hydroxyvitamin D < 25 nmol/L. Abnormal CCA-IMT was defined
as CCA-IMT≥ 0.8 mm. Plaque was defined as a focal structure that encroaches into the arterial lumen of≥ 0.5 mm or
50 % of the surrounding IMT value. Significant stenosis was defined as peak-systolic velocities≥ 125 cm/s and
end-diastolic velocities≥ 40 cm/s.
Results: The vitamin D deficiency and non-deficiency groups did not differ significantly in terms of abnormal
CCA-IMT (P = 0.443), carotid plaque (P = 0.349), and carotid stenosis (P = 0.554). No significant correlation
between serum 25-hydroxyvitamin D levels and CCA-IMT (P = 0.693) was found. On a backward multiple linear
regression model, serum 25-hydroxyvitamin D levels was not associated with CCA-IMT, abnormal CCA-IMT, or
plaque presence.
Conclusions: No important association between serum 25-hydroxyvitamin levels and carotid atherosclerosis
was found in CKD patients.
Keywords: Vitamin D, Parathyroid hormone, Carotid atherosclerosis, Carotid intima-media thickness, Carotid
plaque, Chronic kidney disease
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Background
Atherosclerosis is characterized by the accumulation
of lipids and fibrous cap in the arteries [1]. It com-
monly affects coronary and carotid arteries. Carotid
atherosclerosis includes a spectrum of intima-media
thickening, plaque formation, stenosis, and eventu-
ally occlusion. Several stages of the atherogenic
process have been described, starting from endothe-
lial dysfunction, subendothelial accumulation of
low-density lipoproteins (LDL), and chronic inflam-
mation within the arterial wall leading to formation
of plaque [2, 3].
Vitamin D is a group of fat soluble secosteroids which
play an important role in musculoskeletal health by
regulating calcium and phosphate metabolism [4]. There
are two major forms of vitamin D; ergocalciferol (D2)
and cholecalciferol (D3). The former is found in plants
while the latter is found in humans and is synthesized
following irradiation by ultraviolet B [5]. Both are converted
to 25-hydroxyvitamin D (25(OH)D) by 25-hydroxylase
(CYP2R1) in the liver and are activated by 1α-hydroxylase
(CYP27B1) in the kidney to form 1,25-hydroxyvitamin D
(1,25(OH2)D) [6]. Serum 25(OH)D assay is used to meas-
ure vitamin D status due to its higher serum concentration
and longer half-life. In addition, a developing vitamin D
deficiency is compensated for by increased activation of
1α-hydroxylase which results from increased secretion of
PTH, thus restoring 1,25(OH2)D levels and thereby mask-
ing vitamin D deficiency [7].
The chronic kidney disease (CKD) population has a
high prevalence of carotid atherosclerosis [8, 9] and
vitamin D deficiency [10, 11]. Numerous observational
studies on the association between serum 25(OH)D and
carotid atherosclerosis have showed inconsistent results
[2]. As for the CKD population, there have only been
two studies; one demonstrated an inverse relationship
[12] while the other showed mixed results [13]. Thus,
we have aimed to examine the relationship between
serum 25(OH)D levels and carotid atherosclerosis in
CKD patients as measured by CCA-IMT and the
presence of carotid plaque or stenosis.
Methods
Study design and sampling method
This was a cross sectional study conducted between
September 2015 and March 2016. It has adhered to the
STROBE guidelines for observational studies. A con-
secutive sampling methodology was used for participant
recruitment. The flow diagram is shown in Fig. 1.
Population
A total of 100 pre-dialysis CKD stage 3–4 patients who
attended nephrology, diabetic, and outpatient clinics at
the University of Malaya Medical Centre (UMMC) were
included. Patients who were 70 years old and above, had
underlying coronary artery disease, heart failure, malig-
nancy, active infection, or were on immunosuppressive
drugs or vitamin D supplements were excluded.
Ethics approval and informed consent
Ethics approval (MECID 201412-878) was obtained
from the UMMC Medical Ethics Committee which
governs all research involving humans. Participants
provided written informed consent prior to being en-
rolled in the study.
Data collection procedures
Socio-demographic data, medical history, alcohol and
smoking history, and medication history were obtained
from all subjects. Body mass index (BMI) was calculated
as weight in kilograms divided by height in meters
squared (kg/m2). During the enrolment phase, previous
biochemical tests were reviewed through the laboratory
information system (TD-Web version 11.61B, Techni-
data SAS, France) and results within 2 weeks were
exempted from repeat analysis. The biochemical analysis
of blood samples was conducted in the same laboratory.
The Chronic Kidney Disease Epidemiology Collabor-
ation (CKD-EPI) formula was used to calculate the
estimated glomerular filtration rate (eGFR). Participants
were categorized into three CKD stages: stage 3A
(45–59 mL/min per 1.73 m2), stage 3B (30–44 mL/min
per 1.73 m2) and stage 4 (15–29 mL/min per 1.73 m2)
Fig. 1 Flow diagram of enrolment
Ng et al. BMC Nephrology  (2016) 17:151 Page 2 of 9
according to Kidney Disease Outcome Quality Initiative
(KDOQI) criteria.
Biochemistry assay
Serum 25(OH)D and intact parathyroid hormone (PTH)
levels were determined using direct chemiluminesent im-
munoassay (ADVIA Centaur XP; Siemens Healthcare
Diagnostics, Tarrytown, New York, USA). The detection
limit of the device was <10 nmol/L, with the intra- and
inter-assay coefficient of variations of 4.2 and 11.9 %
respectively. This assay demonstrated comparable per-
formance with the reference standard, liquid chromatog-
raphy tandem mass spectrometry (LC-MS/MS) [14–16].
A mean of 5 nmol/L was assumed for results re-
ported as <10 nmol/L. Vitamin D status was defined
as deficiency (< 25 nmol/L) [17] and non-deficiency
(≥ 25 nmol/L). Serum calcium, inorganic phosphate,
renal profiles and lipid profiles were measured using
colorimetric methods (ADVIA 2400 Chemistry System;
Siemens Healthcare Diagnostics, Tarrytown, New York,
USA). Complete blood counts were analysed using fluor-
escent flow cytometry (XN-10; Sysmex, Kobe, Japan).
Carotid ultrasound
An ultrasound system equipped with high-resolution,
linear-array transducers in the frequency of 4–9 MHz
(Philips iU22; Philips, Seattle, Washington, USA) was
used. Carotid arteries were imaged with L9-3 and L8-4
transducers. It was performed by a single certified
sonographer and images were verified by an experienced
stroke neurologist. All participants underwent a carotid
ultrasound within 2 weeks from 25(OH)D assay to
measure intima-media thickness (IMT) and to assess the
presence of carotid plaque or stenosis at the common
carotid arteries (CCA), internal carotid arteries (ICA),
and external carotid arteries (ECA). Three IMT mea-
surements were obtained at the far walls of the distal,
2 cm from the common carotid artery. The mean of
these three measurements was recorded as the IMT for
that side (left and right). CCA-IMT was defined as the
average of left and right IMT. The images were obtained
at a 30° angle and the length of the segments measured
was 1 cm. The image analysis was done using QLAB
Vascular Ultrasound Quantification software, version
7.1. The analysis was done offline. The presence of
carotid plaque or significant stenosis (≥ 50 %) in the
CCA, bifurcation, and ICA bilaterally were documented.
Abnormal CCA-IMT was defined as CCA-IMT ≥ 0.8 mm
which is beyond the 75th percentile as per the American
Society of Echography Task Force recommendations
[18, 19]. Plaque was defined as a focal structure that
encroaches into the arterial lumen of ≥ 0.5 mm or
50 % of the surrounding IMT value [20]. Significant sten-
osis was defined as peak-systolic velocities ≥ 125 cm/s and
end-diastolic velocities ≥ 40 cm/s as recommended by the
Society of Radiologists in Ultrasound [21].
Statistical analysis
A statistical analysis was performed using the Statis-
tical Package for Social Sciences for Windows, version
23.0 (IBM Corp., Armonk, New York, USA). Clinical
characteristics data was expressed as means ± standard
deviation (SD). Differences between groups were ana-
lysed using independent t-test and one-way analysis
of variance (ANOVA) when the dependent variable
was normally distributed, otherwise by Mann-Whitney
U and Kruskal-Wallis H tests. Appropriate transfor-
mations were made when necessary to ensure normality
or linearity assumptions were met. The correlation
between serum 25(OH)D levels and CCA-IMT was deter-
mined using Pearson’s product-moment correlation coeffi-
cients. Linear regression analysis was performed to
determine the predictors of serum 25(OH)D levels.
Multiple linear regression models were used to identify
the predictors of CCA-IMT, abnormal CCA-IMT, and
plaque presence. Age, gender, race, BMI, smoking habits,
diabetes status, hypertension status, eGFR, serum trigly-
ceride, LDL cholesterol, HDL cholesterol, calcium,
phosphate, PTH, and 25(OH)D levels were taken as
independent variables for modelling. Backward elimin-
ation was applied to remove insignificant variables.
All P-values were calculated two-sided and a value of
< 0.05 was considered as significant.
Results
Demographic and clinical characteristics
A total of 100 CKD stage 3–4 patients were evalu-
ated. The proportion of CKD patients at stage 3A
was 29 %, stage 3B was 40 %, and stage 4 was 31 %.
The mean age of the study population was 59 years.
Fifty-seven percent of them were female. Ethnicity
was comprised of 50 % Malay, 30 % Chinese, and
20 % Indian. The mean BMI was 28.16 kg/m2. The
majority of the patients had hypertension (93 %),
diabetes mellitus (76 %), and dyslipidaemia (79 %).
The mean value of serum 25(OH)D levels was 39.83
± 22.43 nmol/L. The participant’s characteristics were
summarized in Table 1.
A one-way ANOVA was conducted to determine
the difference in mean serum 25(OH)D levels be-
tween various CKD stages. The mean levels for stage
3A, stage 3B, and stage 4 were 42.69 ± 20.68 nmol/L,
40.35 ± 24.42 nmol/L and 36.48 ± 21.60 nmol/L
respectively. A Tukey post hoc analysis revealed that
the differences between the groups were not signifi-
cant (P = 0.558), as shown in Table 2.
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Demographic and clinical characteristics according to
vitamin D status
Table 3 displays the detailed characteristics of partici-
pants according to their vitamin D status. Twenty-nine
percent of the patients had vitamin D deficiency. Gender
(P < 0.001), race (P = 0.002), smoking habits (P = 0.019),
haemoglobin (P = 0.014), serum phosphate (P = 0.038),
and serum PTH (P = 0.014) levels differed significantly
by vitamin D status. The mean serum 25(OH)D levels
for the vitamin D deficiency group was 13.76 ±
6.31 nmol/L while the non-deficiency groups was
50.48 ± 17.30 nmol/L.
Predictors of Serum 25(OH)D Levels
Univariate linear regression analysis showed that age
(P = 0.023), male gender (P < 0.001), Chinese ethnicity
Table 1 Characteristics of participants
Variables Participants
(n = 100)
Age, years 59.05 ± 8.48
Male 43 (43.0)
Race, Malay/Chinese/Indian 50/30/20
Weight, kg 73.96 ± 16.94
Height, cm 162.03 ± 8.08
BMI, kg/m2 28.16 ± 5.77
Smokers 19 (19.0)
Diabetes mellitus 76 (76.0)
Hypertension 93 (93.0)
Dyslipidemia 79 (79.0)
Total cholesterol, mmol/L 4.44 ± 1.37
Triglyceride, mmol/L 1.81 ± 0.80
HDL cholesterol, mmol/L 1.20 ± 0.34
LDL cholesterol, mmol/L 2.44 ± 1.18
CKD, Stage 3A/3B/4 29/40/31
Urea, mmol/L 9.82 ± 3.43
Creatinine, mmol/L 167.62 ± 57.53
eGFR, mls/min/1.73 m2 36.49 ± 12.12
Hemoglobin, g/dL 11.96 ± 1.77
Ca2+, mmol/L 2.26 ± 0.11
PO4
2-, mmol/L 1.25 ± 0.23
PTH, pmol/L 8.01 ± 7.09
25(OH)D, nmol/L 39.83 ± 22.43
Data in parentheses denote percentages
25(OH)D 25-hydroxyvitamin D, BMI body mass index, CKD chronic kidney
disease, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein,
LDL low-density lipoprotein, PTH intact parathyroid hormone
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25(OH)D 25-hydroxyvitamin D, CKD chronic kidney disease, SE standard error
of mean, Ref reference group







Age, years 57.52 ± 8.10 59.68 ± 8.61 0.098
Gender <0.001
Male 4 (13.8) 39 (54.9)
Female 25 (86.2) 32 (45.1)
Race 0.001
Malay 17 (58.6) 33 (46.5)
Chinese 2 (6.9) 28 (39.4)
Indian 10 (34.5) 10 (14.1)
Weight, kg 75.56 ± 20.24 73.30 ± 15.51 0.764
Height, cm 161.24 ± 7.88 162.36 ± 8.19 0.534
BMI, kg/m2 28.92 ± 6.86 27.84 ± 5.28 0.401
Smokers 1 (3.4) 18 (25.4) 0.011
Diabetes mellitus 24 (82.8) 52 (73.2) 0.440
Hypertension 26 (89.7) 67 (94.4) 0.410
Dyslipidemia 23 (79.3) 56 (78.9) 1.000
Total cholesterol, mmol/L 4.81 ± 1.75 4.29 ± 1.16 0.111
Triglyceride, mmol/L 2.06 ± 0.97 1.70 ± 0.69 0.093
HDL Cholesterol, mmol/L 1.22 ± 0.40 1.19 ± 0.32 0.920
LDL Cholesterol, mmol/L 2.70 ± 1.53 2.33 ± 0.99 0.244
CKD 0.450
Stage 3A 6 (20.7) 23 (32.4)
Stage 3B 12 (41.4) 28 (39.4)
Stage 4 11 (37.9) 20 (28.2)
Urea, mmol/L 9.18 ± 3.34 10.08 ± 3.46 0.196
Creatinine, mmol/L 165.21 ± 61.38 168.61 ± 56.30 0.587
eGFR, mls/min/1.73 m2 34.17 ± 11.58 37.44 ± 12.28 0.223
Hemoglobin, g/dL 11.28 ± 1.60 12.23 ± 1.77 0.014
Ca2+, mmol/L 2.26 ± 0.10 2.27 ± 0.11 0.678
PO4
2-, mmol/L 1.31 ± 0.21 1.22 ± 0.23 0.038
PTH, pmol/L 11.49 ± 10.33 6.33 ± 3.97 0.014
25(OH)D, nmol/L 13.76 ± 6.31 50.48 ± 17.30 <0.001
Data in parentheses denote percentages
25(OH)D 25-hydroxyvitamin D, BMI body mass index, CKD chronic kidney
disease, eGFR estimated glomerular filtration rate, HDL high-density lipoprotein,
LDL low-density lipoprotein, PTH intact parathyroid hormone
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(P < 0.001), smoking habits (P = 0.001), diabetes mel-
litus (P = 0.004), haemoglobin (P < 0.001), serum tri-
glyceride (P = 0.041), serum LDL Cholesterol (P = 0.018),
and serum PTH (P = 0.045) levels were predictors of
serum 25(OH)D levels. Chinese ethnicity was the stron-
gest predictor among all, as shown in Table 4.
Carotid outcomes of participants
Among the participants, 23 % had abnormal CCA-IMT
and 67 % had carotid plaque. Carotid stenosis was only
found in three subjects within the entire cohort, as
shown in Table 5. Carotid outcomes were not signifi-
cantly different among CKD stages.
Carotid outcomes of participants according to vitamin D
status
The vitamin D deficiency and non-deficiency groups did
not differ significantly in terms of abnormal CCA-IMT
(P = 0.443), carotid plaque (P = 0.349), and carotid sten-
osis (P = 0.554), as shown in Table 6.
Association between Serum 25(OH)D Levels and Carotid
Atherosclerosis
Correlation between Serum 25(OH)D Levels and CCA-IMT
Pearson’s product-moment correlation was used to
examine the relationship between serum 25(OH)D levels
and CCA-IMT. Figure 2 shows that no significant cor-
relation (P = 0.693) was found.
Predictors of CCA-IMT, abnormal CCA-IMT, and plaque
presence
Multiple linear regression analyses were performed to
assess the association between serum 25(OH)D levels
and CCA‐IMT, abnormal CCA‐IMT, and plaque
presence. A backward elimination method adjusting for
potential confounders namely age, gender, race, BMI,
smoking habits, diabetes status, hypertension status,
eGFR, serum triglyceride, LDL cholesterol, HDL choles-
terol, calcium, phosphate, and PTH levels was applied.
No significant association between serum 25(OH)D
levels and CCA-IMT, abnormal CCA-IMT, and plaque
presence was found. Notably, smoking habits was signifi-
cantly associated with CCA-IMT (P = 0.003) and it pre-
dicted abnormal CCA-IMT (P = 0.003). Chinese
ethnicity predicted abnormal CCA-IMT (P = 0.012) and











Diabetes mellitus -0.283 0.004
Hypertension 0.116 0.252
Triglycerideb -0.205 0.041
LDL Cholesterolb -0.239 0.018







Linearity, normality of residuals, independence of residuals and
homoscedasticity assumptions met. No significant outliers, high leverage
points or highly influential points
β standardized coefficient, Ref reference group, BMI body mass index, eGFR
estimated glomerular filtration rate, HDL high density lipoprotein, LDL low
density lipoprotein, PTH intact parathyroid hormone
a reflection of square root data transformation
b logarithmic data transformation
Table 5 Carotid outcomes of participants
Variable Participants
(n = 100)
Abnormal CCA-IMT 23 (23.0)
CCA-IMT, mm 0.724 ± 0.227
Left CCA, mm 0.731 ± 0.244
Right CCA, mm 0.711 ± 0.265
Plaque 67 (67.0)





Left ICA 6 (6.0)
Left ECA 1 (1.0)





Right ICA 10 (10.0)
Right ECA 3 (3.0)
Stenosis 3 (3.0)
Data in parentheses denote percentages
CCA-IMT common carotid artery intima-media thickness, CCA common carotid
artery, ECA external carotid artery, ICA internal carotid artery
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plaque presence (P = 0.020) whilst serum PTH levels
predicted plaque presence only. Table 7 displays the final
step of each regression model.
Discussion
The inverse relationship between serum 25(OH)D levels
and cardiovascular diseases has been observed in epi-
demiological studies. However, no conclusions can be
draw on the causality of this relationship. In fact, inter-
ventional studies have failed to show that vitamin D-
raising interventions decreased cardiovascular events
[22, 23]. The main findings of our study are: (1) no dif-
ference in CCA-IMT between vitamin D deficient and
non-deficient patients; (2) no correlation between serum
25(OH)D levels and CCA-IMT; and (3) no relationship
between serum 25(OH)D levels and CCA-IMT, abnor-
mal CCA-IMT, and plaque presence in multivariate ana-
lysis which corroborates the findings from interventional
studies.
Contrary to our findings, Yadav et al. reported that
serum 25(OH)D levels were inversely associated with
CCA-IMT in CKD patients [12]. Notably, their study
participants had more severe (stage 4 and 5) CKD stages.
Our study has similar percentage of carotid plaque with
a study by Gracia et al. [13]. Again, no association be-
tween serum 25(OH)D levels and carotid plaque were
observed. Instead, serum PTH levels predicted carotid
plaque presence. To the best of our knowledge, PTH has
only been reported to be associated with vascular calcifi-
cation in animal model [24] and arterial stiffness in both
diabetic patients [25] and postmenopausal women [26].
The link between vitamin D concentrations and ca-
rotid atherosclerosis was not clear, even in non-CKD






Abnormal CCA-IMT 5 (17.2) 18 (25.4) 0.443
CCA-IMT, mm 0.679 ± 0.144 0.742 ± 0.252 0.356
Left CCA, mm 0.685 ± 0.195 0.750 ± 0.261 0.282
Right CCA, mm 0.668 ± 0.165 0.729 ± 0.295 0.566
Plaque 17 (58.6) 50 (70.4) 0.349
Left CCA 11 (37.9) 36 (50.7) 0.276
Bulb 11 (37.9) 36 (50.7) 0.276
Proximal 0 (0.0) 2 (2.8) 1.000
Middle 0 (0.0) 1 (1.4) 1.000
Distal 0 (0.0) 5 (7.0) 0.318
Left ICA 3 (10.3) 3 (4.2) 0.352
Left ECA 0 (0.0) 1 (1.4) 1.000
Right CCA 14 (48.3) 36 (50.7) 1.000
Bulb 13 (44.8) 36 (50.7) 0.662
Proximal 1 (3.4) 0 (0.0) 0.290
Middle 0 (0.0) 0 (0.0) -
Distal 1 (3.4) 3 (4.2) 1.000
Right ICA 0 (0.0) 10 (14.1) 0.059
Right ECA 1 (3.4) 2 (2.8) 1.000
Stenosis 0 (0.0) 3 (3.0) 0.554
Data in parentheses denote percentages
CCA-IMT common carotid artery intima-media thickness, CCA common carotid
artery, ECA external carotid artery, ICA internal carotid artery
Fig. 2 Correlation between serum 25(OH)D levels and CCA-IMT
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population. Blondon et al. (n = 3251) reported that both
vitamin D and PTH had no significant impact on carotid
IMT and plaque in a multi-ethnic cohort with high car-
diovascular risk [27]. Similarly, Deleskog et al. (n = 3430)
found no consistent association between serum
25(OH)D and carotid IMT in a high risk European
population [28].
There are several explanations for the disparate results
observed. Firstly, a longitudinal study has showed that
CKD progression was independently associated with
atheromatosis progression [13]. Serum 25(OH)D levels
also fall with eGFR decline and may therefore result in
false association with atherosclerosis. Secondly, the
demographic profiles of enrolled subjects were different.
Different latitudes receive different amounts of sunlight,
resulting in a different range of baseline serum 25(OH)D
levels and carotid IMT. Countries that are far from the
equator might have a seasonal variation of serum
25(OH)D concentrations and the impact of nadir serum
25(OH)D on carotid IMT might remain despite recovery
of serum 25(OH)D levels. Thirdly, the relationship
between vitamin D and carotid IMT was perhaps
U-shaped, rather than linear [29, 30]. Recently, Van Dijk
et al. suggested that the dip of a U-shaped relationship is
at serum 25(OH)D levels of 50 nmol/L [29]. This might
support the findings of Melamed et al. who proposed a
similar U-shaped relationship between serum 25(OH)D
and all-cause mortality in participants of the Third
National Health and Examination Survey (NHANES III)
[31]. In Blondon’s study [27], two thirds of the participants
had baseline serum 25(OH)D ≥ 50 nmol/L, while most
participants in Deleskog’s study [28] had serum 25(OH)D
between 25 and 75 nmol/L. Analysis of these populations
as a whole might attenuate the relationship between
serum 25(OH)D and carotid atherosclerosis.
The observed non-linear relationship can be explained
by the dualistic roles of vitamin D. It has both protective
and harmful effects on vascular health. The anti-
inflammatory and immune-modulatory properties are
protective against atherosclerosis. It decreases endothelial
oxidative stress, improves vascular muscle tone, inhibits
formation of foam cells, regulates proliferation and
migration of vascular smooth muscle cells (VSMC),
inhibits release of pro-inflammatory cytokines, and
suppresses pro-atherogenic T lymphocytes [3, 5, 32]. On
the other hand, it may up-regulate vitamin D receptor
(VDR) expression inducing osteogenic differentiation and
mineralization of VSMC, promote production of matrix
metalloproteinases leading to vascular remodelling, down-
regulate calcification inhibitor fetuin-A expression, and
increase calcium-phosphate product [33–36].
The renal expression of 1α-hydroxylase is regulated by
serum calcium, phosphate, parathyroid hormone (PTH),
and fibroblast growth factor 23 (FGF23) levels. FGF23 is
a hormone secreted from osteocytes in coordination
with α-Klotho to promote renal phosphate excretion
[37]. FGF23 levels increase at early CKD stages which
results in a decrease of serum α-Klotho and 1,25(OH2)D
levels [38]. Low levels of circulating 1,25(OH2)D via a
negative feedback mechanism causes a rise of PTH
concentrations to stimulate reabsorption of calcium,
bone resorption and 1,25(OH2)D production. PTH also
increases total collagen synthesis and reorganizes colla-
gen in VSMC leading to vascular stiffness [39, 40]. In
addition to secondary hyperparathyroidism, FGF23
excess and Klotho deficiency have been recognized as
novel factors contributing to vascular calcification
[41–43] which might in part explain the link between
CKD progression and atherosclerosis. In a recent
breakthrough, Chang et al. demonstrated the ability of
intermedin1-53 to increase α-Klotho levels which can
suppress vascular calcification and delay the progres-
sion of CKD [44]. Both vascular calcification and
elastin fibres degeneration cause arterial stiffening
[35] which may increase risk of vessel wall damage
and result in atherosclerosis [45]. Hence, α-Klotho defi-
ciency plays a pivotal role in accelerated atherosclerosis.
The strength of our study was the inclusion of a more
comprehensive carotid plaque assessment rather than
solely relying on a carotid IMT measurement. Our study
had several limitations: (1) it included a relatively small
number of patients thus may have a lack of statistical
power; (2) it was a single-centre study so the results
Table 7 Backward multiple linear regression for predictor of
CCA-IMTa, abnormal CCA-IMT and plaque presence
Variable B SE for B β 95 % CI for B P-value
CCA-IMTa
Chinese 0.097 0.055 0.192 -0.012–0.206 0.079
Smoker 0.201 0.064 0.329 0.073–0.330 0.003
Diabetes 0.112 0.057 0.213 -0.001–0.225 0.051
Abnormal CCA-IMT
Chinese 0.289 0.113 0.317 0.064–0.514 0.012
Smoker 0.369 0.121 0.335 0.127–0.610 0.003
25(OH)D -0.004 0.002 -0.235 -0.009-<0.001 0.073
Plaque Presence
Chinese 0.265 0.112 0.257 0.043–0.488 0.020
PTHa 0.325 0.158 0.222 0.010–0.641 0.043
Age, gender, race, BMI, smoker, diabetes status, hypertension status, eGFR,
serum triglyceride, LDL cholesterol, HDL cholesterol, calcium, phosphate, PTH,
and 25(OH)D levels were included in the model. Linearity, normality of
residuals, independence of residuals and homoscedasticity assumptions met.
No multicollinearity problem. No significant outliers
B unstandardized regression coefficient, SE standard error of the coefficient, β
standardized coefficient CI confidence interval, 25(OH)D 25-hydroxyvitamin D,
PTH intact parathyroid hormone
a logarithmic data transformation
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cannot be generalised; and (3) other confounding fac-
tors, such as α-Klotho and FGF23 were not taken
into account.
Conclusion
Our study showed that there was no important associ-
ation between serum 25(OH)D and CCA-IMT.
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